AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8957970 — intervention group
Group type: COMPARATOR
Intervention: Conventional carbon dioxide pneumoperitoneum
Number of subjects: 26
Study 1432468 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein-predominant formula
Number of subjects: 28
Study 1432468 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula
Number of subjects: 28
Study 1432468 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey-hydrolysate formula
Number of subjects: 28
Study 6241563 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g tiapride daily for 3 weeks
Number of subjects: 29
Study 6241563 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 29
Study 30857452 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy for fast ventricular arrhythmia (VA)
Number of subjects: 1790
Study 30857452 — intervention group
Group type: EXPERIMENTAL
Intervention: Shocks for fast VA
Number of subjects: 1790
Study 30857452 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing for fast VA
Number of subjects: 1790
Study 30857452 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy for slow VA
Number of subjects: 1790
Study 30857452 — intervention group
Group type: EXPERIMENTAL
Intervention: Shocks for slow VA
Number of subjects: 1790
Study 30857452 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing for slow VA
Number of subjects: 1790
Study 30857452 — intervention group
Group type: COMPARATOR
Intervention: No ICD therapy
Number of subjects: 1790
Study 29356759 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified primary continuous prophylaxis started by 25 IU/kg once per week, increased to twice or 3 times a week according to defined bleeding events.
Number of subjects: 33
Study 27974526 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening perindopril
Number of subjects: 85
Study 27974526 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning perindopril
Number of subjects: 85
Study 27974526 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening perindopril with CPAP
Number of subjects: 85
Study 27974526 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning perindopril with CPAP
Number of subjects: 85
Study 27974526 — intervention group
Group type: COMPARATOR
Intervention: Placebo (evening and morning)
Number of subjects: 85
Study 25280396 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip resurfacing (RHA)
Number of subjects: 82
Study 25280396 — intervention group
Group type: COMPARATOR
Intervention: Small diameter metal‐on‐metal total hip arthroplasty (MoM THA)
Number of subjects: 82
Study 23848944 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (CBT)
Number of subjects: 263
Study 23848944 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based problem-solving therapy (PST)
Number of subjects: 263
Study 23848944 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 263
Study 21411716 — intervention group
Group type: EXPERIMENTAL
Intervention: Project MYTRI tobacco prevention program
Number of subjects: 14085
Study 21411716 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 14085
Study 18167386 — intervention group
Group type: EXPERIMENTAL
Intervention: TY2 (Tyrian SPE and One‐Step Plus, following the manufacturer's recommendation [two coats])
Number of subjects: 29
Study 18167386 — intervention group
Group type: EXPERIMENTAL
Intervention: TY4 (Tyrian SPE and One‐Step Plus, with four coats)
Number of subjects: 29
Study 18167386 — intervention group
Group type: EXPERIMENTAL
Intervention: OS4 (phosphoric acid and One‐Step Plus, with four coats)
Number of subjects: 29
Study 18167386 — intervention group
Group type: EXPERIMENTAL
Intervention: OS2 (phosphoric acid and dental adhesive [One‐Step Plus, Bisco], following the manufacturer's recommendation [two coats])
Number of subjects: 29
Study 18167386 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 29
Study 16752268 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral micronized 17beta‐estradiol
Number of subjects: 25
Study 16752268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 14521771 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cholesterol and low-saturated fatty acid diet
Number of subjects: 120
Study 14521771 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 120
Study 11030682 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 gauge, 16 mm, orange hub needle
Number of subjects: 119
Study 11030682 — intervention group
Group type: COMPARATOR
Intervention: 23 gauge, 25 mm, blue hub needle
Number of subjects: 119
Study 9091013 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine amniotomy
Number of subjects: 1540
Study 9091013 — intervention group
Group type: COMPARATOR
Intervention: Selective amniotomy
Number of subjects: 1540
Study 8406348 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 5‐micrograms doses of hepatitis B recombinant DNA yeast vaccine at 0 and 1 month (group 1)
Number of subjects: 318
Study 8406348 — intervention group
Group type: EXPERIMENTAL
Intervention: Three 5‐micrograms doses of hepatitis B recombinant DNA yeast vaccine at 0, 1 and 6 months (group 2)
Number of subjects: 318
Study 8406348 — intervention group
Group type: EXPERIMENTAL
Intervention: Three 10‐micrograms doses of plasma‐derived hepatitis B vaccine (group 3)
Number of subjects: 318
Study 2869540 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 40 mg orally followed by IV saline
Number of subjects: 40
Study 2869540 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo followed by IV diazepam 10 mg (Diazemuls)
Number of subjects: 40
Study 2869540 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam and IV diazepam
Number of subjects: 40
Study 29570018 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer Liquid
Number of subjects: 33
Study 29570018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 29570018 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Gluma and Placebo)
Number of subjects: 33
Study 27645620 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of ofatumumab combined with bendamustine or fludarabine and cyclophosphamide chemotherapy
Number of subjects: 82
Study 27645620 — intervention group
Group type: EXPERIMENTAL
Intervention: Mega dose of ofatumumab combined with bendamustine or fludarabine and cyclophosphamide chemotherapy
Number of subjects: 82
Study 27645620 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 82
Study 24835849 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 745
Study 24835849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 745
Study 22799111 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50/100mg
Number of subjects: 50
Study 22799111 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride 1/2 mg
Number of subjects: 50
Study 19647973 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in the Minimal Intervention for Stress‐related mental disorders with Sick leave (MISS)
Number of subjects: 46
Study 19647973 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by GPs
Number of subjects: 46
Study 18266669 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion at 5 microg/min
Number of subjects: 80
Study 18266669 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion at 10 microg/min
Number of subjects: 80
Study 18266669 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion at 15 microg/min
Number of subjects: 80
Study 18266669 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion at 20 microg/min
Number of subjects: 80
Study 18266669 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol in control subjects
Number of subjects: 80
Study 18266669 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol in patients with vagotonic AF
Number of subjects: 80
Study 18266669 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol in patients with adrenergic AF
Number of subjects: 80
Study 18266669 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol in patients with random AF
Number of subjects: 80
Study 15715892 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice a day for 2 months
Number of subjects: 23
Study 15715892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 14534335 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 1106
Study 14534335 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa plus cytarabine
Number of subjects: 1106
Study 14534335 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete cytogenetic remission with at least 3 log reduction
Number of subjects: 1106
Study 14534335 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of less than 3 log
Number of subjects: 1106
Study 14534335 — intervention group
Group type: EXPERIMENTAL
Intervention: Not in complete cytogenetic remission
Number of subjects: 1106
Study 11302252 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU 150 mg/m2/i.v. followed by temozolomide 550 mg/m2/p.o. (Arm A)
Number of subjects: 45
Study 11302252 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU 100 mg/m2/i.v. followed by temozolomide 400 mg/m2/p.o. (Arm B)
Number of subjects: 45
Study 11302252 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide pharmacokinetics
Number of subjects: 45
Study 11302252 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and periodic pulmonary function testing
Number of subjects: 45
Study 8135447 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (100 mg of recombinant tissue plasminogen activator)
Number of subjects: 0
Study 8135447 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy of watchful waiting with appropriate backup
Number of subjects: 0
Study 2811366 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide treatment (250 mg q.i.d. with hydrocortisone 50 mg b.i.d. for 2 weeks, then 25 mg b.i.d.)
Number of subjects: 6
Study 946507 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin prophylaxis
Number of subjects: 820
Study 946507 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin prophylaxis)
Number of subjects: 820
Study 30638888 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable polymer sirolimus-eluting stent
Number of subjects: 0
Study 30638888 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stent
Number of subjects: 0
Study 28580882 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus fulvestrant
Number of subjects: 669
Study 28580882 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 669
Study 26219732 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq™
Number of subjects: 120
Study 26219732 — intervention group
Group type: EXPERIMENTAL
Intervention: Glidescope™
Number of subjects: 120
Study 26219732 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastrach™
Number of subjects: 120
Study 23618477 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnosine (1500 mg)
Number of subjects: 25
Study 20691839 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI with adjunctive enoxaparin and abciximab
Number of subjects: 205
Study 20691839 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis with enoxaparin followed by reteplase
Number of subjects: 205
Study 18257780 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg before each main meal)
Number of subjects: 109
Study 16774151 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild overnight hypoxia (SaO2 approximately 90%)
Number of subjects: 11
Study 16774151 — intervention group
Group type: COMPARATOR
Intervention: Medical air (control)
Number of subjects: 11
Study 12638640 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0
Study 11004354 — intervention group
Group type: EXPERIMENTAL
Intervention: Home management
Number of subjects: 1670
Study 9376455 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 21
Study 9376455 — intervention group
Group type: COMPARATOR
Intervention: Drug-free (after haloperidol)
Number of subjects: 21
Study 1587076 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping medication under open-label conditions (weeks 190 to 210)
Number of subjects: 48
Study 1587076 — intervention group
Group type: COMPARATOR
Intervention: Stopping anorexiants under double-blind conditions (weeks 160 to 190)
Number of subjects: 48
Study 1587076 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer from fenfluramine plus phentermine to no medication
Number of subjects: 48
Study 1587076 — intervention group
Group type: COMPARATOR
Intervention: Transfer from fenfluramine plus phentermine to placebo under double-blind conditions
Number of subjects: 48
Study 3751746 — intervention group
Group type: EXPERIMENTAL
Intervention: East region
Number of subjects: 0
Study 3751746 — intervention group
Group type: COMPARATOR
Intervention: South-West region
Number of subjects: 0
Study 3751746 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regions
Number of subjects: 0
Study 31661198 — intervention group
Group type: EXPERIMENTAL
Intervention: M72/AS01E vaccine
Number of subjects: 3575
Study 31661198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3575
Study 29584832 — intervention group
Group type: EXPERIMENTAL
Intervention: Close contact casting
Number of subjects: 0
Study 29584832 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study 27502791 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) and arachidonic acid (AA) supplementation
Number of subjects: 129
Study 27502791 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 129
Study 27502791 — intervention group
Group type: EXPERIMENTAL
Intervention: Current DHA status
Number of subjects: 129
Study 24607029 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D treatment
Number of subjects: 1370
Study 24607029 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D treatment with left bundle branch block (LBBB)
Number of subjects: 1370
Study 22577917 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 200
Study 22577917 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 200
Study 22577917 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and Propofol
Number of subjects: 200
Study 20122737 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometer (GAT)
Number of subjects: 100
Study 20122737 — intervention group
Group type: EXPERIMENTAL
Intervention: Pascal dynamic contour tonometer (DCT)
Number of subjects: 100
Study 20122737 — intervention group
Group type: EXPERIMENTAL
Intervention: Reichert Ocular Response Analyzer (ORA)
Number of subjects: 100
Study 20122737 — intervention group
Group type: COMPARATOR
Intervention: Comparison of GAT, DCT, and ORA
Number of subjects: 100
Study 17631314 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg/day
Number of subjects: 420
Study 17631314 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 15 mg/day
Number of subjects: 420
Study 17631314 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 20 mg/day
Number of subjects: 420
Study 17631314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 16135354 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-needle technique
Number of subjects: 24
Study 12087008 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg t.i.d.
Number of subjects: 503
Study 12087008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 503
Study 10412699 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (33 degrees C for 48 to 72 hours)
Number of subjects: 30
Study 7725578 — intervention group
Group type: EXPERIMENTAL
Intervention: YAMIK sinus catheter
Number of subjects: 131
Study 7725578 — intervention group
Group type: COMPARATOR
Intervention: Conventional sinus punctures
Number of subjects: 131
Study 2072226 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified whole milk formula (M)
Number of subjects: 116
Study 2072226 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-hydrolyzed milk formula (HM)
Number of subjects: 116
Study 2072226 — intervention group
Group type: COMPARATOR
Intervention: Wheat noodles and whole milk (N-M)
Number of subjects: 116
Study 2072226 — intervention group
Group type: COMPARATOR
Intervention: Wheat noodles and lactose-hydrolyzed whole milk (N-HM)
Number of subjects: 116
Study 2072226 — intervention group
Group type: EXPERIMENTAL
Intervention: Both milk groups (M and HM)
Number of subjects: 116
Study 2072226 — intervention group
Group type: COMPARATOR
Intervention: Both noodle-milk groups (N-M and N-HM)
Number of subjects: 116
Study 2072226 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified whole milk (M)
Number of subjects: 116
Study 2072226 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-hydrolyzed milk (HM)
Number of subjects: 116
Study 6342332 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg X 3 daily
Number of subjects: 100
Study 6342332 — intervention group
Group type: EXPERIMENTAL
Intervention: High quality bandaging
Number of subjects: 100
Study 6342332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 6342332 — intervention group
Group type: COMPARATOR
Intervention: Low quality bandaging
Number of subjects: 100
Study 30857464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 15108
Study 30857464 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 15108
Study 29853236 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D planning technique
Number of subjects: 62
Study 29853236 — intervention group
Group type: COMPARATOR
Intervention: 2D planning technique
Number of subjects: 62
Study 29853236 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 2D and 3D planning techniques
Number of subjects: 62
Study 27121690 — intervention group
Group type: EXPERIMENTAL
Intervention: RAI with lithium
Number of subjects: 163
Study 27121690 — intervention group
Group type: COMPARATOR
Intervention: RAI alone
Number of subjects: 163
Study 27121690 — intervention group
Group type: EXPERIMENTAL
Intervention: RAI with lithium (women and patients with Graves' disease)
Number of subjects: 163
Study 24689834 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programme
Number of subjects: 0
Study 22570948 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 42
Study 22570948 — intervention group
Group type: COMPARATOR
Intervention: Diet/Exercise
Number of subjects: 42
Study 20026779 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg daily
Number of subjects: 17802
Study 20026779 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17802
Study 18628266 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical conjunctival anaesthesia with a 1:1 mixture of lidocaine 2% and levobupivacaine 0.75%
Number of subjects: 22
Study 18628266 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution
Number of subjects: 22
Study 18628266 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Number of subjects: 22
Study 16198882 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive diastolic heart failure
Number of subjects: 28
Study 16198882 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 28
Study 12392387 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg)
Number of subjects: 24
Study 12392387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9918344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pallidotomy (PVP)
Number of subjects: 13
Study 9918344 — intervention group
Group type: EXPERIMENTAL
Intervention: Posteroventral stimulation (PVS)
Number of subjects: 13
Study 9918344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pallidotomy (PVP) and Posteroventral stimulation (PVS)
Number of subjects: 13
Study 7572686 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20-40 mg/day)
Number of subjects: 919
Study 7572686 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 919
Study 7572686 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin-placebo
Number of subjects: 919
Study 1963015 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg/day (4000 anti-Factor Xa IU), administered in one or two subcutaneous injections
Number of subjects: 0
Study 1963015 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg/day (one or two injections daily)
Number of subjects: 0
Study 1963015 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg/day
Number of subjects: 0
Study 1963015 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg/day, begun 12 h pre-operatively
Number of subjects: 0
Study 1963015 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin 5000 IU tds
Number of subjects: 0
Study 380804 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole, 150 mg/day orally for 3 consecutive days every other week
Number of subjects: 134
Study 380804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 380804 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 134
Study 30064259 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation added to pulmonary rehabilitation
Number of subjects: 45
Study 30064259 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary rehabilitation (control group)
Number of subjects: 45
Study 28570161 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg daily (n=9)
Number of subjects: 17
Study 28570161 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=8)
Number of subjects: 17
Study 28570161 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (matched pairs)
Number of subjects: 17
Study 28570161 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (baseline use in both groups)
Number of subjects: 17
Study 26443655 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ simulation (ISS)
Number of subjects: 25